| Name | Title | Contact Details |
|---|
Aracent Healthcare is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Truly Instrument Limited is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Esprit Home Care is a Leesburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Invendo Medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed. In order to achieve its goal the company first focussed on an application in the diagnosis and treatment of colorectal cancers (CRC). CRC is the second leading cause of cancer death with an estimated annual worldwide death toll of 510,000 people. More than 1 million new cases are diagnosed every year. However 90-100% of colorectal cancers can be avoided if diagnosed early on